A significant increase in patient contributions for vital medications in Cyprus has triggered widespread criticism. This development follows recent reclassifications within the national health system, Gesy, prompting the Federation of Patient Associations (Osak) to call for urgent discussions. Osak is seeking dialogue with the Health Insurance Organisation (HIO) and pharmaceutical companies to address what they describe as a substantial financial burden, particularly affecting vulnerable populations like the elderly.
The core of the controversy revolves around the re-evaluation of drug categories, reportedly linked to the expiry of patents for original pharmaceuticals. Osak contends that this reclassification has inadvertently shifted financial responsibility onto patients, forcing them to pay more for treatments they have historically relied upon. A spokesperson confirmed that "serious repercussions on thousands of patients" have resulted from these changes, which directly impact the cost of essential medicines.
Osak's primary argument is that the current system may encourage treatment choices based on cost rather than purely medical necessity. This issue becomes more pronounced when medications for the same condition, possessing different active substances, are reclassified. Even if clinically interchangeable, these changes can lead to considerably higher co-payments for patients. Osak emphasised that "the choice of medicine by the doctor cannot be determined by the changes in the contribution arising from reclassifications."
This shift is proving particularly challenging for pensioners and individuals with limited financial resources, who now face escalating monthly expenses for their prescribed therapies. These increased costs represent a significant deviation from their established budgets, potentially jeopardising their ability to adhere to vital treatment plans. Osak believes patients should be protected from the financial consequences of patent expiries and market fluctuations.
Complaints have been received from both concerned patients and increasingly frustrated doctors, whose prescribing autonomy may be compromised. Osak has initiated discussions with the HIO to find a resolution that prioritises patient well-being. The current situation highlights a pressing need for greater transparency and a more equitable approach to drug pricing and classification within Gesy, ensuring that financial efficiency does not undermine accessible healthcare.